|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Actelion
|
|
gptkbp:activities
|
endothelin receptor blockade
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:2001
gptkb:United_States
|
|
gptkbp:associated_with
|
improved quality of life
improved survival rates
reduced hospitalization rates
|
|
gptkbp:brand
|
gptkb:Tracleer
|
|
gptkbp:class
|
endothelin receptor antagonist
|
|
gptkbp:clinical_trial
|
Phase III
long-term treatment
improves exercise capacity
reduces symptoms of PAH
|
|
gptkbp:contraindication
|
pregnancy
severe liver impairment
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tracleer
|
|
gptkbp:ingredients
|
gptkb:bosentan
|
|
gptkbp:interacts_with
|
gptkb:warfarin
gptkb:cytochrome_P450_3_A4
gptkb:glyburide
|
|
gptkbp:invention
|
gptkb:2021
gptkb:2022
gptkb:2023
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_used_for
|
pulmonary arterial hypertension
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Actelion_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Japan
gptkb:Native_American_tribe
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:previous_name
|
gptkb:bosentan
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:research_focus
|
cardiovascular diseases
pulmonary hypertension
endothelin antagonism
|
|
gptkbp:safety_features
|
gptkb:2015
gptkb:2018
gptkb:2020
|
|
gptkbp:scholarships
|
report any signs of liver problems
monitor liver function
avoid pregnancy
|
|
gptkbp:side_effect
|
headache
edema
liver function abnormalities
|
|
gptkbp:storage
|
room temperature
|